29 April 2016 - Treatment of follicular lymphoma to be added to Gazyvaro’s approved uses.

The EMA has recommended extending the authorised indication of Gazyvaro (obinutuzumab) to treat patients with follicular lymphoma. The medicine is to be used in combination with bendamustine in patients who were previously treated with chemotherapy.

Gazyvaro was first authorised in the EU in July 2014 for use in combination with chlorambucil in patients with previously untreated chronic lymphocytic leukaemia.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/04/news_detail_002522.jsp&mid=WC0b01ac058004d5c1